Daan Gene (002030) Incident Review: Third-quarter Results Exceed Expectations, Capacity Expansion Expected and Expected to Continue the COVID-19 Advantage
Daan Gene (002030) 2020 Semi-Annual Report Review: COVID-19 Screening in the Post-Pandemic Era Continues to Benefit from Strict Performance in the Second Half of the Year
Daan Gene (002030): First-half performance exceeded expectations, and the company's development reached a milestone inflection point
Daanquin (002030) Annual report comments: overall steady growth business structural change is the weather vane of industry change
Daanquin (002030) comments: the rise of independent laboratory new business type is expected to have high growth in the future.
[Galaxy of China] Da'an Gene Review: the rise of independent laboratory new business type is expected for high growth in the future.
[Huajin Securities] Daan Gene: the income of service products has increased significantly, and gene diagnosis has been actively distributed.
Daanquin (002030): a significant increase in revenue from service products and active layout of genetic diagnosis
[Huachuang Securities] Daan Gene: wait and see what happens
Comments on Daanquin's (002030) Annual report: wait and see what happens
达安基因(002030)年报点评:各项业务保持平稳增长
Daanquin (002030) in-depth report: molecular Diagnostics Industry leader Daan The Smiling、Proud Wanderer
达安基因(002030)点评:医投业务逐渐兑现 技术+服务打开巨大市场空间
达安基因(002030)
【华创证券】达安基因:平台构建初具规模,有利长期发展
达安基因(002030)季报点评:平台构建初具规模 有利长期发展
达安基因(002030)调研简报:公布定增方案 大幅加码基因诊断技术平台建设
Daan Gene (002030) Brief Review: Issuing an Additional 1.5 Billion Dollars to Consolidate Industry Status, Employee Shareholding and Promoting State-owned Enterprise Reform in Colleges and Universities
达安基因(002030)中报点评:关注公司的战略布局和长期投资价值
达安基因(002030):前瞻性布局基因诊断行业